Yes, Vivitrol is officially considered a medication-assisted treatment (MAT) for addiction. SAMHSA, the federal agency that oversees substance abuse treatment in the United States, explicitly includes extended-release injectable naltrexone (the active ingredient in Vivitrol) as part of MAT for opioid use disorder. The FDA has approved three types of medications for MAT, and Vivitrol represents one of those three categories.
The Three FDA-Approved MAT Medications
MAT uses medications combined with counseling and behavioral therapies to treat substance use disorders. The FDA recognizes three types of medications for opioid use disorder, and they work in fundamentally different ways:
- Methadone is a full opioid agonist, meaning it activates the same brain receptors that opioids do, but in a controlled, steady way that reduces cravings and withdrawal.
- Buprenorphine (found in Suboxone and similar products) is a partial agonist, meaning it partially activates opioid receptors, enough to ease cravings but with a ceiling effect that limits its intensity.
- Naltrexone (Vivitrol) is an opioid antagonist, meaning it blocks opioid receptors entirely without activating them at all.
All three are considered MAT despite working through completely different mechanisms. The distinction matters because some people assume MAT only refers to agonist-based treatments like methadone or buprenorphine, which can create physical dependence. Vivitrol does not.
How Vivitrol Works Differently
Vivitrol’s active ingredient, naltrexone, binds to opioid receptors in the brain but does not activate them. This competitive binding blocks the effects of any opioids a person might use, essentially making them unable to get high. According to the FDA label, naltrexone “is a pure opioid antagonist that does not lead to physical or psychological dependence.”
This is a sharp contrast to methadone and buprenorphine, which both produce some degree of opioid-like effects. If you stop taking methadone or buprenorphine abruptly, you’ll experience withdrawal symptoms. Stopping Vivitrol does not cause withdrawal, though it does remove the protective blockade against relapse.
What Vivitrol Is Approved to Treat
Vivitrol carries FDA approval for two separate conditions. For alcohol dependence, it’s approved for patients who can abstain from drinking in an outpatient setting before starting treatment. For opioid dependence, it’s approved specifically for relapse prevention after a person has already completed detoxification. It is not a detox medication itself.
This dual approval is worth noting because MAT discussions often focus on opioid use disorder, but Vivitrol’s role in treating alcohol dependence is equally recognized.
The Opioid-Free Requirement
Starting Vivitrol requires being completely opioid-free for a minimum of 7 to 14 days beforehand. This includes prescription painkillers, street drugs, cough and cold medicines containing opioids, and even other MAT medications like buprenorphine or methadone. People transitioning from methadone or buprenorphine may need to wait up to two weeks because those drugs leave the body more slowly.
If someone still has opioids in their system when they receive a Vivitrol injection, the medication can trigger sudden, severe withdrawal, sometimes serious enough to require hospitalization. This opioid-free period is one of the biggest practical barriers to starting Vivitrol compared to buprenorphine, which can be started while a person is still in mild withdrawal.
How It’s Administered
Vivitrol is given as a 380 mg injection into the gluteal muscle once every four weeks. A healthcare provider must administer each shot, alternating sides with each visit. It cannot be self-administered, taken as a pill (though oral naltrexone exists as a separate product), or injected intravenously.
The monthly schedule is part of what makes Vivitrol appealing for some people. There’s no daily pill to remember or skip, and no medication to divert or misuse. Once the injection is given, the medication works continuously for about a month.
Effectiveness for Relapse Prevention
In a multi-site pilot study, people receiving Vivitrol for opioid use disorder stayed in treatment at a rate of 66% over six months. Relapse-free survival during that period was estimated at 30 to 45%, compared to 20 to 30% for those receiving treatment without the medication. Those numbers reflect real-world conditions with justice-involved populations, a group that typically faces higher relapse risk.
These results are meaningful but also illustrate that Vivitrol is not a cure. It works best as one component of a broader treatment plan that includes counseling and support, which is the entire premise behind MAT: medication alone isn’t the full answer, but it significantly improves outcomes when combined with behavioral treatment.
Why the Classification Confusion Exists
The question of whether Vivitrol “counts” as MAT usually comes from a real tension in how people think about addiction treatment. Some treatment programs, courts, and insurance plans have historically treated MAT as synonymous with methadone or buprenorphine, sometimes viewing Vivitrol as fundamentally different because it doesn’t involve any opioid agonist activity. On the other side, some programs promote Vivitrol as the only “truly drug-free” option, implying that agonist-based MAT isn’t real recovery.
Both perspectives misunderstand the federal definition. SAMHSA and the FDA classify all three medications as MAT. The choice between them depends on individual circumstances: where someone is in their recovery, whether they can complete the opioid-free period required for Vivitrol, their history with each medication, and their personal preferences. No single MAT medication is universally better than the others.